Drugs of abuse usurp the mechanisms underlying synaptic plasticity in areas of the brain, a process that may contribute to the development of addiction. We previously reported that GABAergic synapses onto dopaminergic neurons in the ventral tegmental area (VTA) exhibit long-term potentiation (LTP GABA ) blocked by in vivo exposure to morphine. The presynaptically maintained LTP requires the retrogradely released nitric oxide (NO) to activate a presynaptic cGMP signaling cascade. Previous work reported that inhibitory GABA A receptor synapses in the VTA are also potentiated by cAMP. Here, we explored the interactions between cGMP-dependent (PKG) and cAMP-dependent (PKA) protein kinases in the regulation of these GABAergic synapses and LTP GABA . Activation of PKG was required for NO-cGMP signaling and was also essential for the induction of synaptically elicited LTP GABA , but not for its maintenance. Synapses containing GABA A receptors were potentiated by NO-cGMP signaling, whereas synapses containing GABA B receptors on the same cells were not potentiated. Moreover, although the cAMP-PKA system potentiated GABA A synapses, synaptically induced LTP GABA was independent of PKA activation. Surprisingly, however, raising cGMP levels saturated potentiation of these synapses, precluding further potentiation by cAMP and suggesting a convergent end point for both signaling pathways in the regulation of GABAergic release. We further found that persistent GABAergic synaptic modifications observed with in vivo morphine did not involve the presynaptic cAMP-PKA cascade. Taken together, our data suggest a synapse-specific role for NO-cGMP-PKG signaling pathway in opioid-induced plasticity of VTA GABA A synapses.
INTRODUCTION
Long-term potentiation (LTP) and long-term depression (LTD) are long-lasting synaptic modifications proposed to underlie many examples of experience-dependent plasticity (Malenka and Bear, 2004) . Over the last decade, rapid, druginduced synaptic plasticity has been reported at excitatory glutamatergic synapses in addiction-related brain circuits, suggesting that LTP-and LTD-like changes may also contribute to the development of addiction (Ungless et al, 2001; Hyman et al, 2006; Kauer and Malenka, 2007) . Recent evidence suggests that drug-induced plasticity of ventral tegmental area (VTA) GABAergic synapses may also contribute to the development of addictive behaviors (Mansvelder et al, 2002; Melis et al, 2002; Liu et al, 2005; Nugent et al, 2007; Pan et al, 2008) .
Opioids rapidly increase VTA dopamine (DA) cell firing and output through disinhibition, that is, by reducing the tonic inhibition provided by local interneurons . Recently, we reported that 24 h after in vivo morphine exposure nitric oxide (NO)-dependent LTP GABA is blocked, providing a long-lasting mechanism by which opioids can enhance the excitability of DA neurons and may contribute to the reinforcing effects of opioids. LTP GABA is heterosynaptic, initiated by glutamate release onto NMDA receptors on the postsynaptic DA neuron. Activation of NO synthase by intracellular Ca 2 + generates NO, which then travels retrogradely to activate soluble guanylate cyclase (sGC) in neighboring presynaptic GABAergic nerve terminals. Increased levels of cGMP, presumably acting in presynaptic terminals, promote longlasting potentiation of GABA release at these synapses (Nugent et al, 2007) . In the context of opiate addiction, it is important to further investigate the precise cellular mechanisms underlying LTP GABA .
Cyclic GMP-dependent protein kinase (PKG) is present in neurons throughout the brain, and is a major target of NOcGMP signaling (el-Husseini et al, 1995; Wang and Robinson, 1997) . PKG has previously been implicated in the induction and maintenance of synaptic plasticity (Zhuo et al, 1994; Wu et al, 1998; Lu et al, 1999; Santschi et al, 1999; Lu and Hawkins, 2002; Monfort et al, 2002 Monfort et al, , 2004 Chien et al, 2003; Liu et al, 2003) . The cAMP-PKA signaling pathway also regulates synaptic plasticity in many brain regions Kandel, 1994, 1998; Weisskopf et al, 1994; Salin et al, 1996a, b; Castro-Alamancos and Calcagnotto, 1999; Linden and Ahn, 1999; Mellor et al, 2002) . Several studies have implicated cAMP-PKA signaling in responses to drugs of abuse. Following acute withdrawal from chronic morphine, cyclic AMP-dependent increases in GABA release in different regions, including the VTA, have been reported (Bonci and Williams, 1997; Chieng and Williams, 1998; Ingram et al, 1998) . Furthermore, Melis et al (2002) reported that cAMP-PKA signaling is required for induction of a long-lasting potentiation of VTA GABAergic synapses after a single exposure to ethanol. Given that opioids can modulate the release of GABA through an interaction with the presynaptic cAMP cascade (Williams et al, 2001 ), here we have investigated the roles of PKG and PKA as likely downstream targets for cGMP and cAMP in LTP GABA .
MATERIALS AND METHODS

Preparation of Brain Slices
Preparation of slices was as described previously (Jones et al, 2000; Nugent et al, 2007) . Sprague-Dawley rats (15-21 days old) were deeply anesthetized using isoflurane and quickly decapitated in accordance with the Brown University Institutional Animal Care and Use Committee guidelines. The brain was rapidly removed into ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): 126 NaCl, 21.4 NaHCO 3 , 2.5 KCl, 1.2 NaH 2 PO 4 , 2.4 CaCl 2 , 1.2 MgSO 4 , 11.1 glucose, 0.4 ascorbic acid, saturated with 95% O 2 /5% CO 2 (pH 7.4). Horizontal midbrain slices containing the VTA (250 mm thick) were cut using a vibratome, stored for at least 1 h at 351C, and transferred to a recording chamber where the slice was submerged in warmed ACSF.
Electrophysiology
Midbrain slices were continuously perfused with ACSF (no ascorbic acid) at 28-321C at 2-4 ml/min. To study GABA A receptor-mediated synaptic transmission, 6,7-dinitroquinoxaline-2,3-dione (DNQX;10 mM), strychnine (1 mM), and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 1 mM) were added to block AMPA-, glycine-, and A1 adenosine receptors, respectively. To isolate GABA B receptor-mediated IPSCs, the superfusion medium contained 2-amino-5-phosphonopentanoic acid (AP-5; 100 mM), DNQX (10 mM), picrotoxin (100 mM), strychnine (1 mM), eticlopride (1 mM) and 7-hydroxyiminocyclopropan [b] chromen-1a-carboxylic acid ethyl ester (CPCCOEt; 50 mM) to block NMDA, AMPA, GABA A , glycine, D 2 -, and mGluR1 receptors, respectively. The GABA B R IPSCs were entirely blocked by the GABA B receptor antagonist CGP55845 (10 mM). Patch pipettes were filled with (in mM): 125 KCl, 2.8 NaCl, 2 MgCl 2 , 2 ATP-Na + , 0.3 GTP-Li + , 0.6 EGTA, and 10 HEPES. To record GABA A Rmediated IPSCs, cells were voltage-clamped at À70 mV except during HFS, and the cell input resistance and series resistance were monitored throughout the experiment; experiments were discarded if these values changed by more than 10% during the experiment. GABA B R IPSCs were recorded from cells voltage-clamped at -50 mV (see below).
If the steady-state h-current was greater than 60 pA during a step from À50 to À100 mV, the neuron was considered a DA neuron. A recent study showed that expression of I h alone is not sufficient to identify DA cells unequivocally (Margolis et al, 2006 , but see the review by Chen et al, 2008) . Therefore in each set of our experiments, a subset of the neurons recorded from and reported here are possibly non-dopaminergic neurons.
GABA A R-mediated IPSCs were stimulated at 0.1 Hz (100 ms) using a bipolar stainless steel stimulating electrode placed 200-500 mm rostral to the recording site in the VTA. GABA B R-mediated IPSCs were stimulated using a train of stimuli; 10 pulses of 250 ms at 66 Hz, repeated once every 60 s (Bonci and Williams, 1996; Fiorillo and Williams, 2000) . LTP GABA was induced by stimulating afferents at 100 Hz for 1 s, the train was repeated twice 20 s apart (high-frequency stimulation; HFS). Just before HFS, the recorded neuron was taken from voltage-clamp and into bridge mode, so that the HFS trains were delivered with the membrane potential free to vary.
Statistics
Data are presented as means ± SEM. Significance was determined using a Student's unpaired t-test with significance level of po0.05. Levels of LTP are reported as averaged IPSC amplitudes for 5 min just before LTP induction compared with averaged IPSC amplitudes during the 5 min period from 15 to 20 min after HFS using a Student's paired t-test. Paired-pulse ratios (50 ms interstimulus interval) were measured over 5 min epochs of 30 IPSCs each as previously described (Nugent et al, 2007) .
Drug Application
Drugs were bath-applied at known concentrations for at least 15 min before HFS. Control experiments were interleaved with experiments in which drugs were bath-applied. To assess drug effects, IPSC amplitudes were averaged for 5 min during the peak response and were compared with 5 min of averaged data before drug application. Salts and all other drugs were obtained from Sigma-Research Biochemicals International or Tocris Bioscience, except for KT5823, obtained from Calbiochem.
Treatment with Morphine
Rats (15-21 days old) were maintained on a 12-h light/dark cycle and provided food and water ad libitum. They were injected intraperitoneally with either 10 mg/kg morphine or a comparable volume of saline, placed in a new cage for 2 h, and then returned to the home cage. They were killed for brain slice preparation 24 h after injection.
RESULTS
As we reported previously (Nugent et al, 2007 , GABAergic synapses on VTA DA neurons undergo LTP in response to patterned local electrical stimulation (LTP GABA , Figure 1a) . LTP GABA appears to be expressed by an increase in presynaptically released GABA, as the paired-pulse ratio and coefficient of variation change after induction (Nugent et al, 2007) .
NO is not Needed to Sustain LTP GABA Sustained activity of protein kinases, such as protein kinase C (PKC) and calcium calmodulin kinase type II (CaMKII), have been proposed to be involved in the maintenance and expression of LTP (Lisman, 1985; Lisman and Goldring, 1988; Malinow et al, 1988; Chen et al, 2001; Yang et al, 2004) . In VTA DA cells, the production of presynaptic cGMP in response to NO release triggers LTP GABA . We first asked whether constitutive release of NO is necessary to sustain LTP GABA , or whether instead, a brief exposure is sufficient to persistently enhance GABA release. Consistent with our previous results, the NO donor, SNAP (S-nitroso-N-acetylpenicillamine; 200-400 mM), potentiated GABA A R IPSCs, resembling LTP GABA (Figure 1b and c ). Yet we observed that when the NO scavenger, PTIO (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide, 300 mM), was added after the NO donor elicited synaptic potentiation, the SNAP-induced potentiation did not decay back to control values (Figure 1b and c) . The inability of PTIO to reverse the potentiation strongly suggests that the maintenance of LTP GABA does not require the persistent presence of NO.
The NO-cGMP Signaling Cascade Activates PKG to Potentiate GABAergic Synapses Consistent with our previous findings, the cGMP analog, pCPT-cGMP (8-(p-chlorophenylthio)-cGMP; 100 mM), potentiated GABAergic IPSCs (Figure 2a ) suggesting that NO-mediated activation of guanylate cyclase is required for NO to enhance GABA release. Furthermore, pCPT-cGMP is a selective activator of PKG, with little effect on cyclic nucleotide-gated ion channels or phosphodiesterases (Wang and Robinson, 1997) . If NO-cGMP signaling must activate PKG to potentiate GABAergic synapses, then a PKG inhibitor should prevent the potentiation induced either by SNAP or pCPT-cGMP. As predicted, KT5823, a selective (500 nM) also prevents the potentiation of IPSCs by 100 mM pCPT-cGMP (104 ± 6% of pre-SNAP values, n ¼ 6). KT5823 was applied at least 15 min before the addition of pCPT-cGMP. Inset: averaged IPSCs recorded during single experiment in KT5823 and after 15 min in pCPTcGMP. (d) KT5823 (500 nM) has no effect on basal GABAergic transmission (113 ± 6% of pre-drug values, n ¼ 5). Inset: averaged IPSCs recorded during single experiment before and after 10 min in KT5823.
PKG inhibitor which interferes at the level of the ATPbinding site of the PKG catalytic domain (Hidaka and Kobayashi, 1992) , prevented the potentiation induced by either the NO donor (Figure 2b ) or the cGMP analog ( Figure 2c ). These data support the idea that the sequential activation of the presynaptic sGC and PKG downstream from NO promotes GABA release in these synapses. In addition, KT5823 did not reduce basal synaptic transmission (Figure 2d ), implying that PKG activity is not required to maintain basal GABA release from these terminals.
Sequential Activation of GC, and then PKG is Necessary for the Induction of LTP GABA but not for its Maintenance
We further explored the role of PKG in the induction and maintenance of LTP GABA in response to HFS. Application of KT5823 entirely blocked the induction of LTP GABA ( Figure 3a ). If persistent PKG activity is also necessary for the maintenance of LTP GABA , synaptic potentiation should be reversed if PKG activity is inhibited after induction. To test this hypothesis, we bath applied KT5823 10 min after induction of LTP GABA using synaptic stimulation (HFS). KT5823 had no significant effect on the maintenance of LTP GABA ( Figure 3b ). Furthermore, after pCPT-cGMP washout and addition of KT5823, the IPSC amplitude remained potentiated, confirming that the maintenance of the potentiation did not require persistent activity of PKG once the LTP was induced (178 ± 4% of pre-drug values, n ¼ 3). Taken together, these findings suggest that the induction of LTP GABA requires transient activation of PKG, but the expression of LTP GABA does not require persistent activity of this kinase.
GABA B Synapses are not Potentiated in Response to cGMP
Anatomically and functionally distinct sets of GABAergic afferents innervate VTA DA neurons at inhibitory synapses containing either GABA B or GABA A receptors. For example, GABAergic axons from outside the VTA, such as the nucleus accumbens or ventral pallidum, target GABA B R-containing synapses, whereas GABA A R-containing synapses most likely receive their main input from the axons of local GABAergic interneurons in the VTA Sugita et al, 1992; Cameron and Williams, 1993) . As GABA A R LTP is altered after morphine exposure in vivo, and drugs of abuse can also influence GABA B receptor synapses, we next asked whether the NO-cGMP signaling cascade could modulate GABA B synapses. We evaluated the effects of SNAP and pCPT-cGMP on GABA B IPSCs recorded from VTA DA neurons. Unlike GABA A synapses, after bath application of either the NO donor or the cGMP analog, GABA B synapses were not potentiated ( Figure 4 ). These findings show that the molecular machinery for NO-cGMP signaling does not potentiate all GABA-releasing axons in the VTA, but is selective for GABA A R-associated synapses, most likely arising from local VTA GABAergic neurons. The NO-cGMP potentiating mechanism is either absent or non-functional in the VTA GABA B nerve terminals originating from GABAergic neurons outside the VTA.
Activation of Adenylyl Cyclase Potentiates GABA A Synapses and Occludes Further Potentiation by HFS
A rise in presynaptic cAMP following activation of adenylyl cyclase facilitates neurotransmitter release at many synapses, and is involved in the induction and expression of LTP at many excitatory and inhibitory synapses (Briggs et al, 1988; Greengard et al, 1991; Cameron and Williams, 1993; Chavez-Noriega and Stevens, 1994; Kandel, 1994, 1998; Weisskopf et al, 1994; Bonci and Williams, 1996; Salin et al, 1996a; Bonci and Williams, 1997; Castro-Alamancos and Calcagnotto, 1999; Linden and Ahn, 1999; Mellor et al, 2002) . Furthermore, PKA activation has previously been shown to potentiate GABA A R synapses on VTA DA neurons (Melis et al, 2002) . Therefore, we explored the interactions of the cAMP cascade with LTP GABA using forskolin (10 mM) to activate adenylyl cyclase. We confirmed that forskolin enhanced GABAergic responses (Figure 5a and b) and this enhancement was associated with a decrease in the paired-pulse ratio, suggesting that it is likely due to enhanced GABA release, also seen during LTP GABA (Melis et al, 2002; Nugent et al, 2007) . Dideoxyforskolin, a biologically inactive analog that does not stimulate adenylyl cyclase, had no effect on GABA Amediated responses (Figure 5b ). Furthermore, once the potentiation by forskolin had plateaued, HFS failed to produce further synaptic potentiation (Figure 5a and c) . Thus, forskolin mimicked and occluded LTP GABA through the activation of adenylyl cyclase and the subsequent rise in cAMP. PKA is the major downstream target for cAMP, and if the activation of PKA mediates synaptic enhancement, Sp-cAMPS (a cAMP mimic and specific activator of PKA) should also enhance GABA release. Consistent with this hypothesis, we found that Sp-cAMPS (20 mM) also potentiated GABA A IPSCs and occluded further potentiation induced by HFS (Figure 6a-c) .
Activation of PKA Through the cAMP Signaling Pathway is not Necessary for the Induction or Expression of LTP GABA
Together, these findings indicate that elevation of cAMP or PKA activation enhances synaptic strength through a presynaptic mechanism shared by LTP GABA . However, these experiments do not address whether cAMP/PKA signaling are required for LTP GABA . To test this idea, a specific PKA inhibitor, Rp-cAMPS (20 mM) was bath applied before HFS and remained throughout the experiment. An even lower concentration of Rp-cAMPS was sufficient to block PKA in an earlier study (Gutlerner et al, 2002) . The induction and expression of LTP GABA was entirely unaffected by bath application of Rp-cAMPS (Figure 6d ). These data suggest that the cAMP-PKA signaling pathway is not required for LTP GABA but apparently shares downstream mechanisms with LTP GABA that underlie the long-lasting enhancement of GABA release from these terminals.
PKG and PKA Signaling Pathways Converge Onto Common Downstream Mechanisms to Sustain the Potentiation of GABAergic Synapses
Our data thus far indicate that elevation of either cGMP or cAMP levels enhances GABA release through the activation of PKG and PKA, respectively, as shown schematically in Figure 7a . PKA and PKG share common substrates that could serve as a mechanism for convergence. If these two pathways share a common target that promotes persistently enhanced GABA release, saturation of potentiation induced by one signaling pathway should preclude further potentiation through the other. To test this idea, we first bath-applied SNAP to potentiate GABAergic synapses through the NOcGMP-PKG pathway. Once the potentiation by SNAP had plateaued, application of forskolin did not cause further synaptic potentiation (Figure 7b, c) . This finding points to a convergence point for PKG and PKA in expressing and sustaining the increased GABA release. However, a trivial explanation might be that when intracellular levels of cGMP or cAMP are sufficiently high, there is cross-activation of kinases by the cyclic nucleotides (Wang and Robinson, 1997) . To rule out this possibility, we examined the effects of Forskolin activated adenylyl cyclase to increase GABAergic transmission, whereas dideoxyforskolin had no effect on GABA A -mediated responses (forskolin cells, filled circles: 191 ± 22% of pre-drug values, n ¼ 10; dideoxyforskolin cells, open circles: 98 ± 6% of pre-drug values, n ¼ 3). Inset: forskolin-induced potentiation was accompanied by a decrease in the paired-pulse ratio (PPR), suggesting an increase in presynaptic GABA release after forskolin. Five-minute blocks of data are shown (PPR before forskolin: 1.02 ± 0.13; in forskolin: 0.78 ± 0.05; po0.05). (c) After the IPSCs in forskolin reached a stable potentiated level, HFS was delivered. Forskolin-induced potentiation occluded further potentiation of IPSCs by HFS (85 ± 0.6% of pre-HFS values, n ¼ 7). Only the portion of the experiment after forskolin potentiation has plateaued is shown.
forskolin on GABAergic synapses in the persistent presence of the PKG inhibitor, KT5823. If the increased levels of cAMP cross-activate PKG (which would subsequently potentiate these synapses), inhibition of PKG should reduce this potentiation. In contrast, in the presence of the PKG inhibitor, forskolin was still able to induce potentiation comparable with that seen with forskolin alone suggesting that cross talk between these two pathways cannot explain our results. Instead, the simplest explanation of our data is that the two signaling cascades act on a common target to promote a sustained enhancement of GABA release. Further confirmation of this interpretation comes from bath-application of forskolin for only 10 min. The potentiation induced by brief application of forskolin did not require the persistent activation of PKA and still occluded the further potentiation by HFS, suggesting that both kinases converge on a downstream mechanism that is necessary for LTP GABA (99.5 ± 1% of pre-HFS values, n ¼ 4).
A Single In Vivo Morphine Exposure has no Effect on the Presynaptic cAMP-PKA Signaling Pathway
Our recent work has shown that in vivo treatment with morphine persistently modulates GABAergic synaptic plasticity as a result of interference with presynaptic NOcGMP signaling (Nugent et al, 2007) . The cAMP-PKAdependent potentiation of the same GABAergic synapses is also reportedly altered 24 h following ethanol exposure (Melis et al, 2002) . m-opioid receptors are negatively coupled to adenylyl cyclase through G o , and in the VTA, m-opioid drugs acutely depress GABAergic synaptic transmission Williams et al, 2001; Nugent et al, 2007) . In fact, one of the effectors of opioid receptor activation to decrease GABA release is also the inhibition of adenylyl cyclase. On the basis of our present results, which suggest that cGMP and cAMP signaling cascades coexist in VTA GABAergic synapses, we tested whether the interaction of in vivo morphine with cAMP signaling in presynaptic terminals has the potential to interfere with synaptic potentiation by the cAMP-PKA pathway. To address this question, rats were treated either with morphine (10 mg/kg i.p.) or with saline, and 24 h after treatment, the effects of forskolin (10 mM) were tested on GABAergic synapses. Synapses from both saline-and morphine-treated animals were potentiated after exposure to forskolin (Figure 8a-c) , suggesting that the presynaptic cAMP-PKA pathway is unaltered after morphine exposure, in contrast to morphine's effect on the NO-PKG signaling cascade involved in LTP GABA . This result also confirms that the site of disruption of the NO signaling by morphine is upstream to the unidentified converging mechanism for both PKG and PKA. 
DISCUSSION
Here we have investigated the involvement of PKG and PKA in the induction and expression of LTP GABA . Furthermore, we provide evidence for the synapse-specificity of NO signaling at VTA GABA A synapses and confirm that in vivo morphine persistently and specifically modulates the plasticity of these synapses through an interaction with the NO signaling pathway without an associated change in the coexistent cAMP signaling cascade.
The NO-cGMP-PKG and cAMP-PKA Signaling Cascades Both Potentiate GABAergic Synapses
Increasing levels of NO exogenously using SNAP, or application of a cGMP analog, pCPT-cGMP, potentiates GABAergic synapses onto VTA DA neurons. Inhibition of PKG prevented the potentiation induced by NO or cGMP, supporting the role of PKG as the downstream effector from NO-cGMP. However, inhibition of PKG had no effect on basal GABAergic tone, suggesting that constitutive PKG activity is not necessary to maintain basal levels of GABA release. Cyclic GMP-dependent protein kinase is a serinethreonine kinase that mediates most of the effects of cGMP. Two different classes of PKG have been reported, PKG I and PKG II. Although PKG I is highly localized in cerebellar Purkinje cells and a few other sites in brain, the ubiquitous distribution of PKG II and its major localization in neuronal processes make it a major target in mediating cGMP effects in the brain (Wang and Robinson, 1997; de Vente et al, 2001; Williams et al, 2001; Jouvert et al, 2004) . Given that pCPT-cGMP is also a specific PKG II activator, PKG II rather than PKG I is the most likely kinase mediating the potentiation of VTA GABA release.
Several studies have shown that stimulation of AC by forskolin increases the release of GABA at VTA GABAergic synapses (Cameron and Williams, 1993; Williams, 1996, 1997) . We also found that either forskolin treatment or application of a cAMP analog/PKA activator potentiates the GABAergic synapses. We next asked whether the PKG and PKA signaling pathways interact with one another to increase GABA release from these GABAergic terminals. Potentiation of the synapses by using an NO donor prevented subsequent potentiation by forskolin, most likely because these synapses possess the molecular machinery for both NO-cGMP-PKG and cAMP-PKA signaling pathways, with both pathways converging on common downstream effectors to potentiate the GABAergic synapses. PKA and PKG share common phosphorylation substrates, and identification of this unknown converging mechanism in GABAergic release machinery deserves further study. Alternatively, it is formally possible that PKG might phosphorylate an unknown cellular target that could in turn inhibit activation of either AC or PKA.
Synapse Specificity of the NO-cGMP-PKG Signaling to GABA A Synapses
The NO-cGMP signaling pathway can control GABAergic synaptic transmission and plasticity at GABA A R synapses (Stern and Ludwig, 2001; Li et al, 2002; Yu and Eldred, 2005) , but many studies also suggest the involvement of GABA B Rs in drug addiction-related behaviors (Humeniuk et al, 1993; Cameron and Williams, 1994; Bonci and Williams, 1996; Shoji et al, 1997 Shoji et al, , 1999 Boehm et al, 2002; Leite-Morris et al, 2004; Ong and Kerr, 2005) . Chronic exposure to either morphine or cocaine modulates GABA B receptor function (Bonci and Williams, 1996) . Moreover, intra-VTA application of baclofen, a GABA B receptor agonist, interferes with the rewarding properties of intracranial self-stimulation (Willick and Kokkinidis, 1995) , with self-administration of several addictive drugs including heroin (Xi and Stein, 1999) , with morphine-induced place preference (Tsuji et al, 1996) , and with opioid-induced motor sensitization (Leite-Morris et al, 2002 . We therefore next explored the potential presynaptic effects of NO on synaptic transmission mediated by GABA B receptors in the VTA. We found, however, that the NO donor or cGMP analog had no effect on GABA B IPSCs, indicating that the NO signaling pathway selectively potentiates GABA A synapses in the VTA. Although the NO-cGMP signaling pathway did not potentiate GABA B synapses, forskolin activation of the cAMP-PKA pathway has previously been shown to increase GABA B IPSPs (Shoji et al, 1999) . This functional selectivity is not entirely surprising given that distinct sets of GABAergic inputs with distinct characteristics appear to innervate GABA A and GABA B synapses in the VTA. Extrinsic GABAergic afferents arising from forebrain selectively provide synaptic inputs to GABA B receptors, whereas GABA A responses are thought to arise from GABA release from local VTA interneurons Sugita et al, 1992; Shoji et al, 1999) . In addition to the anatomical differences, D1 and 5-HT1A receptors acting through cAMP-PKA machinery are only expressed on presynaptic GABAergic terminals synapsing on GABA B Rs on DA neurons (Sugita et al, 1992; Williams, 1993, 1994) . The synapse specificity of the NO signaling for GABA A synapses we have observed here emphasizes the fact that the two GABAergic inputs to these important DA neurons are quite independent, and modulation or alteration in one will likely spare the other. The distinct machinery available to modulate GABA release in distinct cell populations also potentially provides selective targets for drugs of abuse to exert their modulatory effects on GABAergic neurotransmission. These differences may also be exploited by therapeutic agents targeting only a single type of GABAergic synapse.
PKG but not PKA is Involved in LTP GABA
Raising the levels of either cGMP or cAMP increases GABAergic transmission at GABA A synapses, which mimics LTP GABA . Our earlier work showed the role of cGMP in LTP GABA by 'occlusion' experiments in which prior potentiation induced by a cGMP analog prevented further HFS-induced LTP GABA , presumably by maximally activating the release potentiating machinery. Comparable sets of occlusion experiments were performed here with forskolin and Sp-cAMPS, and we found no further LTP GABA after synaptic HFS, again suggesting an interaction of the cAMP cascade with mechanisms used in LTP GABA . To further clarify the involvement of PKG and PKA in GABAergic plasticity, we used compounds that specifically inhibit protein kinase activity. Although inhibition of PKG completely blocked the induction of LTP GABA , the maintenance of LTP GABA was unaffected. These results show that the induction of NO-dependent LTP GABA is dependent on a rapid activation of PKG; however, the expression and maintenance of LTP GABA does not require persistent PKG activity. On the other hand, inhibition of PKA activity had no effect on the induction or the expression of LTP GABA . The occlusion between SNAP-induced potentiation and forskolin-induced potentiation indicates that LTP GABA requires the NO-cGMP-PKG pathway, and that cAMP-PKA can potentiate GABA A release by a shared cellular mechanism. Phosphorylation of presynaptic proteins provides a potential molecular mechanism to control transmitter release in a nerve terminal, especially in longterm processes such as presynaptic plasticity (Ghijsen and Leenders, 2005) . It is also possible that the cAMP-PKA signaling pathway acts in parallel with PKG to increase phosphorylation of an unknown downstream target whose activation is necessary for the expression of LTP GABA . One possible converging downstream mechanism for both kinases is RIM1a, an active zone protein and PKA substrate that is involved in long-term changes in neurotransmitter release Schoch et al, 2002; Chevaleyre et al, 2006; Chevaleyre et al, 2007) . However, it is not yet known whether RIM1a is a PKG substrate.
The Presynaptic cAMP-PKA Cascade is not Modulated by a Single In Vivo Morphine Exposure
We showed previously that a single in vivo exposure to morphine acts on the NO-cGMP signaling to block LTP GABA at VTA synapses (Nugent et al, 2007) . The m-opioid receptors are coupled through G o to adenylyl cyclase, which in theory could represent an additional morphine target modulated in parallel with the NO-cGMP-PKG signaling cascade. Potentiation of GABA release after withdrawal from chronic morphine resulted from an upregulation of the cAMP-PKA cascade that is sensitive to inhibition by opioids (Chieng and Williams, 1998; Ingram et al, 1998; Shoji et al, 1999; Williams et al, 2001) . Moreover, GABA Amediated synaptic transmission is altered in the VTA by the cAMP-PKA cascade after a single in vivo exposure to ethanol, and this alteration is proposed to provide an initial maladaptive change at the synaptic level (Melis et al, 2002) . However, we found here that increasing cAMP levels in morphine-treated animals still potentiated the GABA A synapses. Although in vivo morphine is able to block an increase in GABA release through the NO-cGMP pathway, GABA transmission by the cAMP-PKA pathway is still able to be potentiated 24 h after morphine. These data also indicate a significant difference between the effects of these two addictive drugs. After 24 h ethanol exposure, GABA A synapses are potentiated and cAMP-PKA cascades elicit no further potentiation (Melis et al, 2002) , whereas 24 h after morphine exposure, the synapses are responsive to cAMP-PKA. It is possible that in response to the two drugs, synaptic changes occur on different time scales, so that an examination of GABA A synapses at different time points following ethanol or morphine may show convergence over time.
One day after morphine exposure LTP GABA is inhibited, presumably removing a normal mechanism limiting DA cell firing rate. This inhibition can be bypassed either by cGMP analogs or activation of PKG, or alternatively by activation of the unaffected cAMP-PKA signaling pathway. Our data therefore suggest that raising cAMP or cGMP levels in GABAergic terminals may represent a useful therapeutic strategy to counteract opioid-induced maladaptive changes at GABAergic synapses. Taken together, these data indicate the synapse-specific role of NO-cGMP-PKG signaling in opioid-induced plasticity of GABAergic synapses. Understanding the effects of chronic exposure to morphine on the NO-cGMP-PKG signaling pathway would also provide insight into how drugs of abuse reshape the reward circuitry. It is possible that repeated exposure to morphine would upregulate the cAMP-PKA pathway, while impairing the NO-cGMP-PKG pathway. It will be of interest to ask whether this modulation by chronic morphine provides a form of homeostatic regulation of inhibitory plasticity in the VTA circuitry during establishment of opiate addiction.
